Modification of HDL and Macrophage Function in Atherosclerosis
动脉粥样硬化中 HDL 和巨噬细胞功能的改变
基本信息
- 批准号:10327718
- 负责人:
- 金额:$ 36.48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-06-01 至 2025-12-31
- 项目状态:未结题
- 来源:
- 关键词:AortaApolipoprotein EApoptoticArachidonic AcidsArterial Fatty StreakAtherogenic DietAtherosclerosisAutomobile DrivingCellsCholesterolChronic Kidney FailureCoronary arteryDevelopmentDiseaseEnzymesEquilibriumFamilyGPR55 receptorGene ExpressionGoalsHigh Density LipoproteinsHydrolysisInflammationInflammatoryIntestinesKidney DiseasesLesionLigandsLipidsLymphLysineModelingModificationMusN-acylphosphatidylethanolamineNAPE-PLDNecrosisPatientsPattern recognition receptorPeripheralPhagocytosisPhenotypePlayProbabilityProteinsReducing dietRestRoleRuptureSmall RNATestingTissuesadductcytokinehuman diseasehypercholesterolemiainhibitorketoaldehydemacrophagemesenteric lymph nodemicrobialmortalitynovelperoxidationprotein expression
项目摘要
A major factor in mortality from atherosclerotic cardiovascular disease is the formation and expansion of
necrotic cores within lesions, which arise when macrophages that normally carry out efferocytosis
(phagocytosis of apoptotic cells) fail to clear apoptotic cells and instead undergo secondary necrosis. This
project seeks to elucidate the contribution of two families of lipids, isolevuglandins (IsoLG) and N-
acylethanolamides (NAEs), that potentially interact through HDL to altered macrophage efferocytic function, as
well as the role of Nape-pld, an enzyme that catalyzes both the formation of NAEs and the degradation of the
IsoLG adducts. We hypothesize that under normal conditions HDL promotes the ability of macrophages to
carry out efferocytosis by 1) accepting the cholesterol that macrophages take up during phagocytosis of
apoptotic cells and 2) delivering NAE precursors to macrophages which use their Nape-pld to hydrolyze these
precursors to NAEs which can promote expression of genes needed for efferocytosis. We hypothesize that in
conditions that promote atherosclerosis, HDL becomes modified by IsoLG which retards efferocytosis by 1)
inhibiting HDL's ability to accept cholesterol and 2) creating ligands recognized by pattern recognition
receptors that drive macrophages to a pro-inflammatory phenotype with high expression of inflammatory
cytokines and low expression of proteins needed for efferocytosis. Thus, IsoLG modification of HDL and
reduced Nape-pld expression combine to suppress the efferocytic capacity of macrophages, leading to the
formation and expansion of necrotic cores which create vulnerable atherosclerotic plaques.
We will test this hypothesis as follows:
Aim 1 will determine if apoAI lysine residues critical to cholesterol efflux are modified by isolevuglandins during
development of atherosclerosis.
Aim 2 will elucidate the mechanisms whereby HDL modified by lipid dicarbonyls potentiate inflammation in
macrophages and determine if these alterations contribute to reduced efferocytosis.
Aim 3 will determine the effects of macrophage Nape-pld deletion on atherosclerosis and macrophage
efferocytic capacity.
动脉粥样硬化性心血管疾病死亡的一个主要因素是血管的形成和扩张
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SEAN Stephen DAVIES其他文献
SEAN Stephen DAVIES的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SEAN Stephen DAVIES', 18)}}的其他基金
Modification of HDL and Macrophage Function in Atherosclerosis
动脉粥样硬化中 HDL 和巨噬细胞功能的改变
- 批准号:
10544067 - 财政年份:2014
- 资助金额:
$ 36.48万 - 项目类别:
Modification of HDL and Macrophage Function in Atherosclerosis
动脉粥样硬化中 HDL 和巨噬细胞功能的改变
- 批准号:
10089343 - 财政年份:2014
- 资助金额:
$ 36.48万 - 项目类别:
Therapeutically Modified Gut Bacteria for Treatment of Obesity
用于治疗肥胖症的治疗性修饰肠道细菌
- 批准号:
8843716 - 财政年份:2013
- 资助金额:
$ 36.48万 - 项目类别:
Therapeutically Modified Gut Bacteria for Treatment of Obesity
用于治疗肥胖症的治疗性修饰肠道细菌
- 批准号:
9042948 - 财政年份:2013
- 资助金额:
$ 36.48万 - 项目类别:
Therapeutically Modified Gut Bacteria for Treatment of Obesity
用于治疗肥胖症的治疗性修饰肠道细菌
- 批准号:
8656665 - 财政年份:2013
- 资助金额:
$ 36.48万 - 项目类别:
Therapeutically Modified Gut Bacteria for Treatment of Obesity
用于治疗肥胖症的治疗性修饰肠道细菌
- 批准号:
8481874 - 财政年份:2013
- 资助金额:
$ 36.48万 - 项目类别:
Transformed Probiotic Bacteria for Treatment of Chronic Diseases
用于治疗慢性疾病的转化益生菌
- 批准号:
7431222 - 财政年份:2007
- 资助金额:
$ 36.48万 - 项目类别:
相似海外基金
Role of human apolipoprotein E isoforms in long-term effects of West Nile Virus exposure on Alzheimer's disease-related behavioral alteration, cognitive injury, neuroinflammation, and neuropathology
人类载脂蛋白 E 同工型在西尼罗河病毒暴露对阿尔茨海默病相关行为改变、认知损伤、神经炎症和神经病理学的长期影响中的作用
- 批准号:
10658408 - 财政年份:2023
- 资助金额:
$ 36.48万 - 项目类别:
A Therapeutic Role for Apolipoprotein-E in the Germ Theory of Alzheimer's Dementia
载脂蛋白-E 在阿尔茨海默氏痴呆病菌理论中的治疗作用
- 批准号:
10601779 - 财政年份:2023
- 资助金额:
$ 36.48万 - 项目类别:
Investigating how apolipoprotein E genotypes modify fatty acid metabolism
研究载脂蛋白 E 基因型如何改变脂肪酸代谢
- 批准号:
RGPIN-2018-06116 - 财政年份:2022
- 资助金额:
$ 36.48万 - 项目类别:
Discovery Grants Program - Individual
Targeting apolipoprotein E for Alzheimer's disease therapy.
靶向载脂蛋白 E 治疗阿尔茨海默病。
- 批准号:
22K06460 - 财政年份:2022
- 资助金额:
$ 36.48万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The role of apolipoprotein E in Alzheimer's adaptive immunity
载脂蛋白E在阿尔茨海默病适应性免疫中的作用
- 批准号:
10674878 - 财政年份:2022
- 资助金额:
$ 36.48万 - 项目类别:
Apolipoprotein E and immunometabolism in Alzheimer's disease
载脂蛋白 E 和阿尔茨海默病的免疫代谢
- 批准号:
10388528 - 财政年份:2022
- 资助金额:
$ 36.48万 - 项目类别:
The role of apolipoprotein E in Alzheimer's adaptive immunity
载脂蛋白E在阿尔茨海默病适应性免疫中的作用
- 批准号:
10515592 - 财政年份:2022
- 资助金额:
$ 36.48万 - 项目类别:
Apolipoprotein E and immunometabolism in Alzheimer's disease
载脂蛋白 E 与阿尔茨海默病的免疫代谢
- 批准号:
10644996 - 财政年份:2022
- 资助金额:
$ 36.48万 - 项目类别:
Apolipoprotein E glycosylation and its role in Alzheimer's disease pathogenesis
载脂蛋白E糖基化及其在阿尔茨海默病发病机制中的作用
- 批准号:
10601040 - 财政年份:2021
- 资助金额:
$ 36.48万 - 项目类别:
Impact of cysteine modifications of apolipoprotein E on the remnant lipoprotein metabolism
载脂蛋白E半胱氨酸修饰对残余脂蛋白代谢的影响
- 批准号:
21K07310 - 财政年份:2021
- 资助金额:
$ 36.48万 - 项目类别:
Grant-in-Aid for Scientific Research (C)